N/A
N=12
Insulin Resistance in Patients With Mood Disorder
Depression · Bipolar Disorder · Insulin Resistance
Bottom Line
View on ClinicalTrials.gov: NCT00242619 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Feb 2017
Primary outcome: Primary: Hamilton Depression Rating Scale (HDRS-21) — 19.9; 13.0 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- rosiglitazone (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- Dec 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hamilton Depression Rating Scale (HDRS-21) |
19.9; 13.0 | — |
| PRIMARY Clinical Global Impression-Severity Scale (CGI-S) |
4.1; 3.3 | — |
Summary
Insulin resistance is known to be associated with mood disorders and cognitive difficulties. The purpose of this study is to treat depressed patients with rosiglitazone (also known as [AKA] Avandia), therefore improving glucose sensitivity, which in turn has the potential to affect mood and thinking. We, the researchers at Stanford University, are recruiting men and women who have been diagnosed with depression, and are willing to participate in this 3 month study. Participation involves neuropsychological testing, 2 blood draws called an oral glucose tolerance test (OGTT), which tests for glucose and insulin levels, and the medication, rosiglitazone. Participants are allowed to continue on their current psychiatric medication.
Eligibility Criteria
Inclusion Criteria:- Current depression
- Insulin resistance
- Current physician/psychiatrist care
- Between the ages of 18-60
- Willing to sign the Human Subjects Protection Consent Form
- Willing to have blood sampling Exclusion Criteria:- Diabetes
- History of unstable heat disease
- Uncontrolled hypertension
- Extensive use of alcohol
- Current use of street drugs
- History of myocardial infarction
- History of cerebrovascular disease
Data sourced from ClinicalTrials.gov (NCT00242619). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.